Publications by authors named "Yubiao Guo"
Background: While allergen-specific immunotherapy (AIT) is acknowledged as an effective treatment, its efficacy varies, and consensus on predictive indicators for AIT responders remains elusive.
Objective: This study aimed to identify alternative parameters for predicting AIT responders based on clinical data collected in daily practice.
Method: We conducted a retrospective analysis of patients with house-dust-mite-driven asthma and/or rhinitis who completed 3 years of subcutaneous AIT (3y-AIT).
Article Synopsis
- Zorifertinib is an experimental cancer drug that targets mutations in the EGFR gene and has shown effectiveness in patients with lung cancer that has spread to the brain.
- A phase 3 trial compared zorifertinib to standard treatments and found that it significantly extended the time patients lived without the disease worsening (progression-free survival).
- Results indicate that zorifertinib may be a better first-line treatment option for non-small cell lung cancer due to its ability to improve survival and manage side effects effectively.
Article Synopsis
- Accurate, non-invasive, and cost-effective methods are essential for improving the diagnosis and management of pulmonary nodules discovered through low-dose computed tomography (LDCT).
- Researchers conducted genome-wide methylation sequencing of lung tissues to create a panel of 263 DNA methylation regions and applied this to blood cell-free DNA (cfDNA) analysis across two patient cohorts.
- They developed a machine learning model that integrates 40 cfDNA methylation biomarkers, age, and CT imaging features, which successfully reduces unnecessary surgeries for benign nodules while promoting timely treatment for lung cancer patients.
Article Synopsis
- * The research utilized genetic data on various types of FAs from the UK Biobank and COPD-related outcomes from the FinnGen consortium to analyze potential associations.
- * Findings indicate that higher levels of saturated fatty acids (SFA) are linked to an increased risk of pneumonia related to COPD, but no strong associations were found for other types of fatty acids.
Background: Sputum immunoglobulin G (Sp-IgG) has been discovered to induce cytolytic extracellular trap cell death in eosinophils, suggesting a potential autoimmune mechanism contributing to asthma. This study aimed to explore the potential origin of Sp-IgG and identify clinically relevant subtypes of Sp-IgG that may indicate autoimmune events in asthma.
Methods: This study included 165 asthmatic patients and 38 healthy volunteers.
Soluble E-Cadherin Contributes to Airway Inflammation in Severe Asthma.
Am J Respir Cell Mol Biol
July 2024
Article Synopsis
- Severe asthma has problems with its airway barrier, and a key protein called E-cadherin can be turned into a different form that might cause issues.
- Researchers studied how this new form, called sE-cadherin, affects asthma by using samples from healthy people and asthma patients, and testing in mice.
- They found that high levels of sE-cadherin in asthma patients are linked to worse symptoms, and blocking it in mice helped reduce inflammation and problems in their airways.
Article Synopsis
- Patients with non-small cell lung cancer who experienced disease progression on EGFR tyrosine kinase inhibitors (TKIs), especially third-generation ones, have limited treatment options available.* -
- The study aimed to compare the effectiveness of ivonescimab in conjunction with chemotherapy versus chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with EGFR variants.* -
- Results showed that the median progression-free survival was significantly higher in the ivonescimab group (7.1 months) compared to the placebo group (4.8 months), indicating a promising benefit for those receiving ivonescimab.*
Background: The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib-refractory, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Herein, we reported the updated data on overall survival (OS) and molecular profiling from the initial phase II study.
Methods: In this study, 180 patients received 225 mg of ensartinib orally once daily until disease progression, death or withdrawal.
Article Synopsis
- * A total of 1332 adult patients were analyzed, revealing that 11.7% had eosinophilic bronchiectasis, which resulted in longer hospital stays (median of 9 days) and higher costs compared to those with normal BEC.
- * Key findings indicated that higher BEC, poorer lung function (FEV1), and elevated platelet levels were significant factors predicting longer hospital durations, highlighting the condition's impact on healthcare resources.
GLUT1 mediates the release of HMGB1 from airway epithelial cells in mixed granulocytic asthma.
Biochim Biophys Acta Mol Basis Dis
March 2024
Asthma is quite heterogenous and can be categorized as eosinophilic, mixed granulocytic (presence of both eosinophils and neutrophils in the airways) and neutrophilic. Clinically, mixed granulocytic asthma (MGA) often tends to be severe and requires large doses of corticosteroids. High mobility group box 1 (HMGB1) is one of the epithelium-derived alarmins that contributes to type 2 inflammation and asthma.
View Article and Find Full Text PDFObjective: DNA methylation alterations are early events in carcinogenesis and immune signalling in lung cancer. This study aimed to develop a model based on short stature homeobox 2 gene ()/prostaglandin E receptor 4 gene () DNA methylation in plasma, appearance subtype of pulmonary nodules (PNs) and low-dose computed tomography (LDCT) images to distinguish early-stage lung cancers.
Methods: We developed a multimodal prediction model with a training set of 257 individuals.
Dysfunction of epithelial barrier is crucial for the development of acute lung injury (ALI). This study was aimed to evaluate the role of glucose transporter 1 (GLUT1) in dysregulation of epithelial tight junction in ALI. GLUT1 was inhibited with specific antagonists WZB117 or BAY876 to see the effects on epithelial tight junction in a well-established LPS-induced mouse ALI model as well as in vitro cultured epithelial cells.
View Article and Find Full Text PDFIntroduction: Asthma is a chronic disease that affects populations worldwide. The purpose of this study was to investigate the expression of TCN1 in sputum and its correlation with inflammation and lung function in asthma.
Methods: We recruited 141 subjects, detected TCN1 mRNA level by quantitative reverse transcription polymerase chain reaction, detected TCN1 protein expression by Western blot, detected TCN1 protein level by enzyme-linked immunosorbent assay, and analyzed the correlation between TCN1 and fraction of exhaled nitric oxide (FeNO), IgE, EOS%, lung functions, and some Th2 cytokines.
Article Synopsis
- * Results show that CSF1 levels are significantly higher in asthma patients, particularly those with severe and eosinophilic asthma, and are linked to increased eosinophil inflammation in the airways.
- * The research suggests that CSF1 interacts with its receptor (CSF1R) and activates the STAT1 signaling pathway, indicating that targeting this pathway could offer new anti-inflammatory treatment options for asthma.
Epithelial CST1 Promotes Airway Eosinophilic Inflammation in Asthma via the AKT Signaling Pathway.
Allergy Asthma Immunol Res
May 2023
Purpose: Epithelial cystatin SN (CST1), a type 2 cysteine protease inhibitor, was significantly upregulated in asthma. In this study, we aimed to investigate the potential role and mechanism of CST1 in eosinophilic inflammation in asthma.
Methods: Bioinformatics analysis on Gene Expression Omnibus datasets were used to explore the expression of CST1 in asthma.
Differential Circular RNA Expression Profiles in Induced Sputum of Patients with Asthma.
Int Arch Allergy Immunol
June 2023
Introduction: circRNA played a role in a variety of diseases. This paper aimed to explore the differentially expressed circRNA in induced sputum cells of asthma patients, so as to provide new potential biomarkers and new ideas for the study of asthma.
Methods: All subjects were from the First Affiliated Hospital of Sun Yat-sen University.
Background: Long non-coding RNA (lncRNA) participates in the immune regulation of lung cancer. However, limited studies showed the potential roles of immune-related lncRNAs (IRLs) in predicting survival and immunotherapy response of lung adenocarcinoma (LUAD). Methods: Based on The Cancer Genome Atlas (TCGA) and ImmLnc databases, IRLs were identified through weighted gene coexpression network analysis (WGCNA), Cox regression, and Lasso regression analyses.
View Article and Find Full Text PDFNovel DNA Promoter Hypermethylation in Nasal Epithelium of Asthma.
Comb Chem High Throughput Screen
June 2023
Background: Abnormal epigenetic alterations influenced by external factors and affecting DNA expression contribute to the development of asthma. However, the role of the nasal epithelium in airway inflammation remains unknown.
Objective: The objective of this study is to identify novel DNA promoter hypermethylation, which suppresses mRNA expression in nasal epithelial of asthma.
Objectives: The SABINA CHINA study aimed to determine prescription data for asthma medication with a focus on SABA and ICS in a representative population of patients with asthma in China.
Methods: SABINA China was a multicentre, observational, cross-sectional study with data collected retrospectively from a convenience sample of 25 tertiary centres across China. Patients (age ⩾ 12 years) with ⩾3 consultations/year were enrolled.
Introduction: CXCL14 involved in inflammatory processes was upregulated in the asthma expression profile datasets in our pilot study. However, the expression of CXCL14 in induced sputum and its potential clinical role in asthma were poorly reported.
Objective: We sought to detect CXCL14 expression in airway epithelium and induced sputum cells of asthma and explore its potential clinical implications.
Background: Asthma is a common chronic airway disease in the world. The purpose of this study was to explore the expression of IL1-RL1 in sputum and its correlation with Th1 and Th2 cytokines in asthma.
Methods: We recruited 132 subjects, detected IL1-RL1 protein level in sputum supernatant by ELISA, and analyzed the correlation between the expression level of IL1-RL1 and fraction of exhaled nitric oxide (FeNO), IgE, peripheral blood eosinophil count (EOS#), and Th2 cytokines (IL-4, IL-5, IL-10, IL-13, IL-33 and TSLP) and Th1 cytokines (IFN-γ, IL-2, IL-8).
Background: The aim of this study is to reveal whether basic salivary proline-rich protein BstNI subfamily 1 (PRB1) may be used as a diagnostic biomarker for type 2-high asthma.
Methods: PRB1 protein levels in the induced sputum of 67 subjects with asthma and 27 controls were determined by an enzyme-linked immunosorbent assay. Correlation analyses between PRB1 in the induced sputum and airway inflammatory indicators were also performed.
Background: Baculoviral IAP repeat-containing 3 (BIRC3) which encodes a member of the IAP family of proteins upregulated in the asthma expression profile dataset. However, there was few research on studying the clinical implication of BIRC3 in asthma.
Objective: To validate BIRC3 expression and its clinical implications in induced sputum of asthma.
Article Synopsis
- Asthma is a chronic respiratory disease, and this study focused on the levels of CEACAM5, a specific protein, in the sputum and serum of patients with asthma.
- The researchers found that CEACAM5 was significantly increased in the sputum and serum of asthma patients, and higher levels correlated with elevated indicators of asthma severity like FeNO and IgE.
- The study suggests that CEACAM5 could be a useful diagnostic marker and target for treatment in managing asthma.
Article Synopsis
- The study investigates the role of PTPRH in asthma, noting that while PTPRH inhibits EGFR in cancer, its function in asthma is not well understood.
- Researchers found elevated levels of PTPRH in asthma patients, correlating it with airway obstruction and markers associated with T-helper2 (Th2) inflammation.
- PTPRH appears to reduce mucus secretion and improve airway function by influencing the EGFR signaling pathway, suggesting potential therapeutic applications for asthma.